
FDA approves venglustat, the first oral therapy for Type 3 Gaucher neurological symptoms.
James Stewart named CIO of Merck KGaA.
James Stewart joined the biopharmaceutical division of Merck KGaA in 2011. Prior to joining Merck KGaA, he had a career with MSD (in the U.S.: Merck & Co.), where he started in Human Resources and progressed through several global business and functional leadership roles.
Source:





